{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:59Z","timestamp":1792787279002,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Health Commission","award":["2022YQ058"],"award-info":[{"award-number":["2022YQ058"]}]},{"name":"Shanghai Foundation for Rare Disease","award":["2021001GB"],"award-info":[{"award-number":["2021001GB"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjpo"],"accepted":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked hypophosphataemia (XLH) is a rare inherited disorder often misdiagnosed and lacking sufficient aetiological treatment. Previous studies have shown that XLH is associated with worse health-related quality of life (HRQoL) and greater economic burden for children and their families compared with the general population, but evidence from China is scarce. This study aimed to comprehensively explore the burden and HRQoL of XLH children in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online retrospective survey of paediatric patients with XLH and their caregivers was conducted nationwide during March to June 2021. A self-administered questionnaire was used to collect socio-demographic, clinical and economic data. The EQ-5D-Y-3L instrument was employed to assess HRQoL, and the health utility score was calculated. Direct medical, non-medical and indirect costs were determined. Multivariate regression analysis was performed to explore potential associations between HRQoL and identified influencing factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 221 subjects with a mean age of 7.25 years, of whom 119 (53.8%) were girls. Most XLH children (63.8%) lived in rural areas, and 39.4% reported a family history. Over 70% experienced misdiagnosis. The average total annual cost per patient was found to be 34 657.85 CNY. Of direct medical costs, patients\u2019 out-of-pocket expenses were substantial. The incidence of catastrophic health expenditure was 19.9%. The means (SD) of EQ-5D-Y-3L health utility and EQ-5D VAS scores were 0.83 (0.14) and 56.07 (10.95). Both univariate and multivariate analyses found older age and lower economic affordability were associated with poorer HRQoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study underscores the significant burden of XLH on paediatric patients and their families in China, both in terms of HRQoL and economic costs. The findings emphasise the importance of early detection, accurate diagnosis, cost-effective targeted interventions and long-term multidisciplinary management strategies to improve the lives of XLH children and their families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjpo-2024-003165","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:15:51Z","timestamp":1741331751000},"page":"e003165","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Disease burden and health-related quality of life among children with X-linked hypophosphataemia in China: a national cross-sectional survey"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-2896","authenticated-orcid":false,"given":"Lin","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Health Policy Research, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Health Policy Research, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Health Policy Research, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingguo","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Foundation for Rare Disease, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"aihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nanjing Children\u2019s Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nanjing Children\u2019s Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Genetics and Endocrinology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children\u2019s Hospital of Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Health Policy Research, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Jin","sequence":"additional","affiliation":[{"name":"Director, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2026010702003095000_9.1.e003165.1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e328358be97"},{"key":"2026010702003095000_9.1.e003165.2","doi-asserted-by":"crossref","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","article-title":"Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium","volume":"12","author":"Laurent","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026010702003095000_9.1.e003165.3","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and Mortality of Individuals With X-Linked Hypophosphatemia: A United Kingdom Real-World Data Analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010702003095000_9.1.e003165.4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0515"},{"key":"2026010702003095000_9.1.e003165.5","unstructured":"Office of the Leading Group of the State Council for the Seventh National Population Census . China population census yearbook 2020. Beijing China Statistics Press; 2021."},{"key":"2026010702003095000_9.1.e003165.6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2018.01056","article-title":"China has officially released its first national list of rare diseases","volume":"7","author":"He","year":"2018","journal-title":"IRDR"},{"key":"2026010702003095000_9.1.e003165.7","doi-asserted-by":"publisher","DOI":"10.1038\/S41581-019-0152-5"},{"key":"2026010702003095000_9.1.e003165.8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026010702003095000_9.1.e003165.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193388","article-title":"Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3","volume":"13","author":"Acar","year":"2018","journal-title":"PLoS One"},{"key":"2026010702003095000_9.1.e003165.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.01.021"},{"key":"2026010702003095000_9.1.e003165.11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2018.01.013","article-title":"Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC\u00ae as Clinical Trial End Points","volume":"21","author":"Theodore-Oklota","year":"2018","journal-title":"Value Health"},{"key":"2026010702003095000_9.1.e003165.12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026010702003095000_9.1.e003165.13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3345\/cep.2022.01459","article-title":"X-linked hypophosphatemic rickets: from diagnosis to management","volume":"67","author":"Park","year":"2024","journal-title":"Clin Exp Pediatr"},{"key":"2026010702003095000_9.1.e003165.14","doi-asserted-by":"publisher","DOI":"10.1530\/EC-13-0103"},{"key":"2026010702003095000_9.1.e003165.15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1515\/jpem-2021-0387","article-title":"Long-term effect of conventional phosphate and calcitriol treatment on metabolic recovery and catch-up growth in children with PHEX mutation","volume":"34","author":"Alikasifoglu","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026010702003095000_9.1.e003165.16","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1210\/clinem\/dgaa495","article-title":"Growth Curves for Children with X-linked Hypophosphatemia","volume":"105","author":"Mao","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010702003095000_9.1.e003165.17","unstructured":"National Medical Products Administration . NMPA conditionally approved burosumab. n.d. Available: https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20210115092032178.html"},{"key":"2026010702003095000_9.1.e003165.18","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624120-00005"},{"key":"2026010702003095000_9.1.e003165.19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-020-00909-3","article-title":"International Valuation Protocol for the EQ-5D-Y-3L","volume":"38","author":"Ramos-Go\u00f1i","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2026010702003095000_9.1.e003165.20","unstructured":"EuroQol Research Foundation . EQ-5D-Y-3L User Guide. 2024. Available: https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides [Accessed 26 Sep 2024]."},{"key":"2026010702003095000_9.1.e003165.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026010702003095000_9.1.e003165.22","unstructured":"WS\/T 423\u20142022, Growth standard for children under 7 years of age, 2022-09-19 launched by National Health Commission of People\u2019s Republic of China. n.d. Available: http:\/\/www.nhc.gov.cn\/fzs\/s7848\/202211\/8b94606198e8457dafb3f8355135f1a3\/files\/e38068f0a62d4a1eb1bd451414444ec1.pdf"},{"key":"2026010702003095000_9.1.e003165.23","unstructured":"WS\/T 612\u20142018, Standard for height level classification among children and adolescents aged 7~18 years, 2018-06-15 launched by National Health Commission of People\u2019s Republic of China. n.d. Available: https:\/\/www.chinacdc.cn\/jkzt\/yyhspws\/xzdc\/201807\/P020180713572925175798.pdf"},{"key":"2026010702003095000_9.1.e003165.24","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1193945","article-title":"Regional catastrophic health expenditure and health inequality in China","volume":"11","author":"Wang","year":"2023","journal-title":"Front Public Health"},{"key":"2026010702003095000_9.1.e003165.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01216-9"},{"key":"2026010702003095000_9.1.e003165.26","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11416988"},{"key":"2026010702003095000_9.1.e003165.27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1507\/endocrj.EJ21-0386","article-title":"Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey","volume":"69","author":"Ito","year":"2022","journal-title":"Endocr J"},{"key":"2026010702003095000_9.1.e003165.28","first-page":"678","article-title":"Genetic and clinical analysis of X-linked hypophosphatemic rickets","volume":"59","author":"Wei","year":"2021","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"2026010702003095000_9.1.e003165.29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jbmr.4331","article-title":"Early Discrimination Between Tumor-Induced Rickets\/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study","volume":"36","author":"Jiajue","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026010702003095000_9.1.e003165.30","unstructured":"National Health Commission of People\u2019s Republic of China . Statistical bulletin on the development of healthcare in China in 2020. 2021. Available: http:\/\/www.nhc.gov.cn\/guihuaxxs\/s10743\/202107\/af8a9c98453c4d9593e07895ae0493c8.shtml"},{"key":"2026010702003095000_9.1.e003165.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239461","article-title":"Do health insurances reduce catastrophic health expenditure in China? A systematic evidence synthesis","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"2026010702003095000_9.1.e003165.32","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00467-024-06427-0","article-title":"Health-related quality of life of children with X-linked hypophosphatemia in Germany","volume":"39","author":"Klein","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"2026010702003095000_9.1.e003165.33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"key":"2026010702003095000_9.1.e003165.34","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.08001","article-title":"Population norms for the EQ-5D-3L in China derived from the 2013 National Health Services Survey","volume":"11","author":"Yao","year":"2021","journal-title":"J Glob Health"},{"key":"2026010702003095000_9.1.e003165.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026010702003095000_9.1.e003165.36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5582\/irdr.2021.01091","article-title":"The usage of enzyme replacement treatments, economic burden, and quality of life of patients with four lysosomal storage diseases in Shanghai, China","volume":"10","author":"Hu","year":"2021","journal-title":"Intractable Rare Dis Res"},{"key":"2026010702003095000_9.1.e003165.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714641"},{"key":"2026010702003095000_9.1.e003165.38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/clinem\/dgad440","article-title":"Efficacy and Safety of Burosumab in X-linked Hypophosphatemia","volume":"109","author":"Wang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010702003095000_9.1.e003165.39","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s11136-015-0971-1","article-title":"Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y","volume":"24","author":"Kind","year":"2015","journal-title":"Qual Life Res"},{"key":"2026010702003095000_9.1.e003165.40","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0538-4","article-title":"Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia","volume":"11","author":"Forestier-Zhang","year":"2016","journal-title":"Orphanet J Rare Dis"}],"container-title":["BMJ Paediatrics Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjpo-2024-003165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:00:43Z","timestamp":1767780043000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpaedsopen.bmj.com\/lookup\/doi\/10.1136\/bmjpo-2024-003165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjpo-2024-003165"],"URL":"https:\/\/doi.org\/10.1136\/bmjpo-2024-003165","relation":{},"ISSN":["2399-9772"],"issn-type":[{"value":"2399-9772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}